The therapeutic effect was first explained by re-activation of a specific tumor-suppressor gene, such as CDKN2A [16], and was then shown to be associated with the suppression of tumor-initiating cells by restoration of multiple pathways in tumor cells [17]. The gene discussed is CDKN2A; the disease is neoplasm.